Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers

Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Columns

Molecular pathology selected abstracts

June 2025—Comprehensive molecular profiling and DNA methylation classification have become critical for diagnosing and managing central nervous system tumors. However, workflows for molecular testing of these tumors are often limited by the cost of equipment and reagents, technical complexity, and lengthy turnaround times. The wide range of alterations that can be present, including MGMT promoter methylation, single nucleotide variants, insertions or deletions (indels), copy number variants, and fusions and structural variants, often necessitate the use of multiple assays for a complete molecular workup. All of these factors have led to a growing demand for molecular assays that are faster, more comprehensive, and more accessible. Recognizing this need, the authors had previously conducted a proof-of-concept study of an adaptive sampling-based nanopore sequencing workflow platform, called Rapid-CNS2, that they had developed.

Newsbytes

June 2025—Whether it’s easier to edit a document created by another source or create more or less the same document from scratch is open to debate. But clinical informaticians at Stanford Health Care, Palo Alto, Calif., are banking on clinicians preferring to assess and adjust versus starting with a blank page. Therefore, the health care system has been conducting trials on the use of generative artificial intelligence to draft patient-centric interpretations of pathology test results that these care providers can review and edit and then share with patients.

Q&A column

June 2025
Q. Our institution performs rapid onsite evaluation (ROSE). In cases in which multiple passes are done, we frequently encounter unsatisfactory specimens (debris, neutrophils, bronchial cells, etc.). These cases are rescreened by a cytotechnologist and pathologist. If the case goes to a different pathologist, those unsatisfactory slides are unnecessarily screened three times. They’re also included in the daily slide workload of the cytotechnologist. Can the onsite pathologist dispose of unsatisfactory Diff-Quik slides and keep just the counter formalin-fixed slides? Since ROSE is provided for that episode, can you comment on billing? Read answer.

Q. Many times a platelet count on an automated hematology system indicates some degree of thrombocytopenia or the analyzer reports a high mean platelet volume or platelet large cell ratio, while a blood smear shows large platelets and/or giant platelets. Is it OK to include a comment in the report that the platelets are adequate or that the count could be due to large platelets, especially with values that indicate marked thrombocytopenia? Read answer.

Put It on the Board

June 2025—A Labcorp survey of more than 100 genetic counselors, including 15 hours of one-one-one conversations, found their three pain points to be balancing patient care and administrative demands, the financial difficulties that complex genetic testing presents, and staying on top of scientific and technologic advances in genetics. Of the time constraints, one genetic counselor at a large health system said, “Anything a lab partner can do, from making their portal easier to get reports or having easy access to someone on their end to help me with some questions, all that gives me more time with the patient.”

Letters

June 2025—I was encouraged to read the CAP TODAY articles on DPYD testing (“Time for wider pretreatment DPYD genotyping?” December 2024; “DPYD genotyping assays—what’s recommended and why,” January 2025). I lost my mother not to her cancer but to a known and preventable toxicity from 5-fluorouracil (5-FU) chemotherapy. She was never informed of the risks of 5-FU if one is DPD deficient nor was she tested for DPD deficiency, a genetic condition that impairs the body’s ability to break down 5-FU and capecitabine. Within days of starting treatment, she developed devastating toxicity that ultimately took her life. We had no warning. Only after she was suffering in the hospital from 5-FU toxicity did I learn about DPYD testing, which could have spared her horrific pain and saved her life. My mom was so easy to live with and so hard to live without. We continue to be heartbroken that her golden years were cut short.

Shorts on Standards: Integrating the Healthcare Enterprise develops vendor-agnostic approach to interoperability of digital pathology data using the DICOM standard

May 2025—Digital pathology has revolutionized tissue-based diagnostics by allowing remote viewing of scanned slides on a display and the use of computational algorithms. However, the implementation of digital pathology has not been without growing pains, with issues arising from the proliferation of proprietary image formats from competing vendor solutions and lack of interoperability between different information systems. Diagnostic data aggregation currently requires toggling between applications that may not be synchronized to patient, specimen, or case. Clinical reporting involves manually pasting diagnostic data between information systems. Measurements, enumeration, and sophisticated analysis of images by machine learning algorithms may also require manual entry of that data.

From the President’s Desk

May 2025—This won’t be news to CAP TODAY readers, but it bears saying: Pathology and laboratory medicine are among the most heavily regulated parts of the health care system in the United States. This regulation is so ingrained in our culture as pathologists that we sometimes deal with it without even thinking. It’s part of our training as residents and remains part of our daily work as pathologists for our entire career.

Clinical pathology selected abstracts

May 2025—Independent risk factors for many cancers include health conditions such as type 2 diabetes and obesity. Glucagon-like peptide-1 receptor agonists (GLA-1RAs) are an effective treatment for these chronic conditions and provide glycemic control, weight reduction, and immunomodulation. In a recent study, GLP-1RAs were associated with lower cancer risk in solid tumor cancers. However, the relationship between GLP-1RAs and hematological cancers has not been explored. Therefore, the authors conducted a study to compare the risk of hematological cancers in patients with type 2 diabetes treated with GLP-1RAs to that of patients with type 2 diabetes treated with metformin or insulin. The primary outcome was a first diagnosis of a hematological cancer within 15 years of an antidiabetic drug being prescribed. The retrospective cohort study used TriNetX, a repository of aggregated electronic health record data of medical encounters for approximately 25 percent of the U.S. population. The platform includes medical information from various age groups, racial and ethnic backgrounds, income levels, and insurance types.

Anatomic pathology selected abstracts

May 2025—Many pancreatic neuroendocrine tumors fall into two major prognostic subtypes based on DAXX/ATRX-induced alternative lengthening of the telomerase phenotype and alpha- and beta-cell-like epigenomic profiles. However, some do not fit into either subtype. Furthermore, despite advanced genotyping, pancreatic neuroendocrine tumors (PanNET) are generally not well characterized in terms of their histologic and hormonal phenotypes. The authors conducted a study to identify new subgroups of PanNET by extending transcription factor signatures and investigating their correlation with histologic, hormonal, molecular, and prognostic findings. One hundred eighty-five PanNET (165 nonfunctioning and 20 functioning), resected between 1996 and 2023, were classified into the subgroups A1, A2, B, C, and D.

Molecular pathology selected abstracts

May 2025—As genomic technology and scientific knowledge advance, so too do their applications in health care. Clinical genetic testing, preimplantation genetic diagnosis (PGD), and heritable human genome editing (HHGE) are an ever-growing and evolving part of genomic medicine. The author explored the significance of lived experiences with genetic disease relative to understanding the severity or seriousness of such diseases in the genomic age. She focused on severity of disease, perceptions of symptoms of disease or associations with disease, and interplay between symptoms of disease and associations with disease. The data presented were collected as part of a larger mixed-methods research project exploring factors that influence attitudes toward the use of HHGE as a potential reproductive choice in the United Kingdom and how identifying those factors could aid the design of future regulations.

MARKETPLACE

TRENDING